NCT00714883终止2 期
A Prospective, Multi-Center Study of the Conor Cobalt Chromium Reservoir Based Stent (NevoTM) With Sirolimus Elution in Native Coronary Artery Lesions (NEVO RES-II)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 3
- 试验地点
- 2
- 主要终点
- target lesion failure (TLF)
研究概览
简要总结
The primary objective of this study is to evaluate the target lesion failure rate of the NEVO Sirolimus-eluting Coronary Stent System.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •* Subjects with atherosclerotic CAD ;
- •* The subject must be \>/= 18 years of age;
- •* Female of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment;
- •* Diagnosis of angina pectoris as defined by stable angina pectoris Canadian Cardiovascular Society Classification (Class I, II, III) OR non-ST segment elevation acute coronary syndrome (Braunwald Classification B\&C) OR OR non-ST segment elevation myocardial infarction ≥ 48 hours from the time of study index procedure OR asymptomatic subjects with a positive stress test;
- •* Indicated treatment of up to two lesions in one or two major coronary arteries (1 target lesion in each of 2 vessels or 2 target lesions in 1 vessel). The target vessel diameter must be \>/= 2.25mm and \50% and \<100% based on a visual estimate.
排除标准
- •ST-elevation MI within 72 hours prior to the index procedure and/or creatine kinase (CK) >2 times the local laboratory upper limits of normal on the day of the index procedure.
- •The patient has undergone target vessel revascularization within 6 months prior to the intended enrolment procedure.
- •Prior stent within 5 mm of target lesion(s);
- •Ostial target lesion(s);
- •Unprotected left main coronary disease with >/= 50% stenosis;
- •Angiographic evidence of thrombus within target lesion(s);
- •Total coronary occlusion or TIMI grade 0 or 1 in the target vessel;
- •Bifurcation disease involving a side branch >/= 2 mm in diameter;
- •Target lesion(s) within a coronary bypass graft (e.g., saphenous vein or arterial graft);
- •Significant calcification or angulation in the target vessel that, in the Investigator's opinion, may preclude stent delivery and deployment;
- •Recipient of heart transplant;
- •Subject with a life expectancy less than 12 months;
- •Known allergies to the following: aspirin, any thienopyridine, heparin, cobalt chromium, contrast agent (that cannot be managed medically), or sirolimus that cannot be managed medically;
- •The patient has contraindication to ASA or to any thienopyridine agent.
- •Currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the study endpoints;
- •Known bleeding or hypercoagulable disorder;
- •Known or suspected active infection at the time of the study procedures;
- •Subject is known to be a prisoner, mentally incompetent, and/or alcohol or drug abuser;
- •Subject has had major surgical or interventional procedures unrelated to this study within 30 days prior to this study or planned surgical or interventional procedures within 30 days of entry into this study, or planned coronary PCI through the end of the study.
- •The patient is currently taking systemic immunosuppressant therapy;
- •The patient has co-morbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study.
结局指标
主要结局
target lesion failure (TLF)
时间窗: 12 months post procedure
次要结局
- Lesion success(Procedure)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
NEXUS Study for the Treatment of de Novo Native Coronary Artery LesionsCoronary Artery DiseaseNCT00231283Cordis Corporation100
已完成
不适用
Treatment for Stress and Mixed Urinary Incontinence and Vaginal Vault ProlapseUrinary Incontinence, StressMixed IncontinenceVaginal Vault ProlapseNCT00223106Medtronic - MITG467
终止
不适用
Comparison of the Conor Sirolimus-eluting Coronary Stent to the Taxus Liberte Paclitaxel-eluting Coronary Stent in the Treatment of Coronary Artery LesionsCoronary AtherosclerosisNCT00606333Cordis Corporation394
已完成
不适用
Coronary Atherectomy System in Patients With Coronary Calcification (CORECT)Calcification of Coronary ArteryNCT05447585Shanghai MicroPort Rhythm MedTech Co., Ltd.239
Unknown
不适用
Safety and Efficacy Study of NOYA Sirolimus-Eluting Stent to Treat Coronary Artery DiseaseCoronary Artery DiseaseNCT02216058Medfavour (Beijing) Medical Co., Ltd2,000